Autologous haematopoietic stem cell transplant – European Clinical Trials Information Network

Study Comparing Two Drug Combinations for Blood Cancer Patients: Rabbit Anti-Human Thymocyte Immunoglobulin vs. Anhydrous Cyclophosphamide

Wed, 29 Apr 2026 15:05:20 +0000

This clinical trial is focused on studying various blood-related cancers, known as hematological malignancies. These include diseases such as Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Chronic Myeloid Leukemia (CML), Multiple Myeloma, Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin’s Lymphoma, and Hodgkin’s Disease. The study aims to compare two different treatment approaches used before a type of stem cell transplant called allogeneic hematopoietic cell transplantation. The two treatments being compared are called Flu-Mel-PTCy and Flu-Mel-ATG. These treatments are used to prepare the body for the transplant by reducing the intensity of the conditioning regimen, which is the process of getting the body ready to receive new stem cells.

The study involves the use of two medications. The first is Thymoglobuline, which contains an active substance called rabbit anti-human thymocyte immunoglobulin. This medication is given through a drip into a vein, known as an infusion. The second medication is Endoxan, which contains anhydrous cyclophosphamide and is administered as an injection into a vein. The purpose of the study is to determine which of these two treatment approaches is more effective in improving the chances of survival without complications related to the transplant.

Participants in the study will receive one of the two treatment regimens before undergoing the stem cell transplant. The study will monitor the participants over a period of time to assess their health outcomes, including survival rates and any potential side effects. The goal is to find out if one of the treatment methods leads to better results in terms of survival without relapse or severe complications. This information will help doctors make informed decisions about the best treatment options for patients with these types of blood cancers.

Study Comparing Fosfomycin and Ciprofloxacin for Preventing Fever in Patients with Acute Leukemia After Chemotherapy or Stem Cell Transplant

Wed, 29 Apr 2026 15:04:05 +0000

This clinical trial is focused on studying a condition known as febrile neutropenia, which often occurs in patients with acute leukemia who are undergoing intensive chemotherapy or receiving a hematopoietic stem cell transplant. Febrile neutropenia is a serious condition characterized by a fever and a low number of neutrophils, a type of white blood cell that helps fight infections. The study aims to compare the effectiveness and safety of two antibiotics, fosfomycin and ciprofloxacin, in preventing this condition.

Participants in the study will be randomly assigned to receive either fosfomycin or ciprofloxacin. Both medications are taken orally, meaning they are swallowed in pill form. The study will monitor the participants over a period of time to see how well each medication works in preventing febrile neutropenia and to ensure the safety of the participants. The goal is to determine if fosfomycin is as effective as ciprofloxacin in preventing infections in these patients.

The study is designed to help improve treatment options for patients with acute leukemia who are at high risk of developing infections due to their weakened immune systems. By comparing these two antibiotics, researchers hope to find the best approach to prevent febrile neutropenia and improve the overall care for patients undergoing chemotherapy or stem cell transplants.

Study on Gene Therapy for Patients with RAG1-Deficient Severe Combined Immunodeficiency Using RAG1-LV-CD34+ Cells

Wed, 29 Apr 2026 14:58:20 +0000

This clinical trial is focused on a rare genetic disorder known as severe combined immunodeficiency (SCID), specifically caused by a defect in the Recombinase Activating Gene 1 (RAG1). SCID is a condition where the immune system is severely weakened, making it difficult for the body to fight off infections. The study is testing a new treatment called RAG1-LV-CD34+ cells, which involves using a patient’s own blood stem cells that have been genetically modified to correct the RAG1 defect. These modified cells are then given back to the patient through an infusion, which is a way of delivering the treatment directly into the bloodstream.

The purpose of the study is to see if this gene therapy is safe and feasible for patients with RAG1-deficient SCID. Participants in the study will receive the gene therapy and will be monitored closely to ensure their safety and to observe how well the treatment works. The study will look at various outcomes, such as the ability of the immune system to recover and function properly, the overall health and survival of the participants, and any potential side effects that may occur.

Throughout the study, researchers will track the participants’ progress over time, including their immune system’s response to the treatment and any changes in their health. The study aims to provide valuable information on the potential of this gene therapy to improve the lives of individuals with RAG1-deficient SCID. Participants will be followed for a period of time to gather comprehensive data on the long-term effects and benefits of the treatment.